AI Article Synopsis
- More than 80% of advanced cancer patients experience weight loss, prompting this study to examine the PARP inhibitor veliparib as a potential treatment for this issue.
- The study leveraged data from a previous phase 1 trial combining veliparib with topotecan, focusing on weight changes in patients undergoing this therapy.
- Results indicated that nearly all patients lost weight, with only one patient experiencing a significant weight gain attributed to fluid accumulation, suggesting that veliparib is not effective for preventing weight loss in advanced cancer patients.
Article Abstract
Background: More than 80% of patients with advanced cancer develop weight loss. Because preclinical data suggest poly (ADP-ribose) polymerase (PARP) inhibitors can treat this weight loss, this study was undertaken to explore the PARP inhibitor veliparib for this indication.
Objective: The current study was undertaken to analyze prospectively gathered data on weight in cancer patients on PARP inhibitors.
Design/setting: The current study relied on a previously published, prospectively conducted phase 1 single institution trial that combined veliparib and topotecan (NCT01012817) as antineoplastic therapy for advanced cancer patients. Serial weight data and, when available and clinically relevant, computerized tomography scans were also examined.
Measurements: The primary endpoint was 10% or greater weight gain from trial enrollment.
Results: Nearly all 60 patients lost weight over time. Only one patient manifested a 10% or greater gain in weight. However, review of computerized tomography L3 images showed this weight gain was a manifestation of ascites. Four other patients gained 5% of their baseline weight. However, findings in two patients with available radiographs showed no evidence of muscle augmentation.
Conclusions: The addition of the PARP inhibitor veliparib to chemotherapy does not appear to result in notable weight gain or in weight maintenance in patients with advanced cancer. Interventions other than PARP inhibitors should be considered for the palliation/treatment of cancer-associated weight loss.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154444 | PMC |
| http://dx.doi.org/10.1089/jpm.2018.0023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Four SNPs in the untranslated region of the NOTCH2 gene involved in reproductive traits in fertile and anestrum Holstein Friesian cattle.
BMC Vet Res
December 2024
Department of Research, Research and Development Station for Bovine, Arad, Romania.
Background: There are no studies belong NOTCH2 gene polymorphism in relation to reproductive and productive traits in Holstein cattle. The objective of the present study was to investigate the effect of NOTCH2 gene polymorphisms on productive and reproductive performance of fertile and anestrum cattle.
Methods: The cattle were classified into anestrus for 3-12 months postpartum (n = 115, 37.
A randomized trial of low-dose thrombolysis, ultrasound-assisted thrombolysis, or heparin for intermediate-high risk pulmonary embolism-the STRATIFY trial: design and statistical analysis plan.
Trials
December 2024
Department of Cardiology, The Heart Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Background: Intermediate-high risk pulmonary embolism (PE) carries a significant risk of hemodynamic deterioration or death. Treatment should balance efficacy in reducing clot burden with the risk of complications, particularly bleeding. Previous studies on high-dose, short-term thrombolysis with alteplase (rtPA) showed a reduced risk of hemodynamic deterioration but no change in mortality and increased bleeding complications.
View Article and Find Full Text PDFFeasibility of the use of Kangaroo mother care in the transfer of preterm and low-birth-weight infants: a two-arm nonrandomized controlled cluster feasibility study of neonatal transport in Cape Coast, Ghana.
BMC Pediatr
December 2024
Department of Nursing and Midwifery, College of Health, Wellbeing and Life Sciences, Sheffield Hallam University, Sheffield, UK.
Background: Despite progress made towards SDG 3, sub-Saharan Africa lags behind the rest of the world, accounting for over 50% of global neonatal deaths. The increased number of hospital births in the region has not reciprocated the reduction in neonatal mortality rates. Sick newborns face uncertain journeys from peripheral facilities to specialized centres arriving in suboptimal conditions, which impacts their outcomes, due partly to the scarcity of dedicated neonatal transport services.
View Article and Find Full Text PDFPredicting lncRNA-protein interactions using a hybrid deep learning model with dinucleotide-codon fusion feature encoding.
BMC Genomics
December 2024
College of Physics and Electronic Information, Gannan Normal University, Ganzhou, 341000, Jiangxi, China.
Long non-coding RNAs (lncRNAs) play crucial roles in numerous biological processes and are involved in complex human diseases through interactions with proteins. Accurate identification of lncRNA-protein interactions (LPI) can help elucidate the functional mechanisms of lncRNAs and provide scientific insights into the molecular mechanisms underlying related diseases. While many sequence-based methods have been developed to predict LPIs, efficiently extracting and effectively integrating potential feature information that reflects functional attributes from lncRNA and protein sequences remains a significant challenge.
View Article and Find Full Text PDFNon-adherence to antenatal iron supplementation and its determinants among pregnant women in 35 sub-saharan African countries: a generalized linear mixed-effects modeling with robust Poisson regression analysis.
BMC Pregnancy Childbirth
December 2024
Department of Public Health, College of Medicine and Health Sciences, Samara University, Samara, Ethiopia.
Background: Despite the integration of iron supplementation into routine antenatal care programs as a nutritional intervention to prevent anemia in pregnant women, the use of this supplement for the recommended duration remains low in sub-Saharan Africa (SSA). Evidence on maternal compliance with iron supplementation at the SSA level is lacking and most of the previous studies have been limited to specific geographic areas. Therefore, the current study used large population survey data from 35 SSA countries to estimate the pooled prevalence of non-adherence and its determinants.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!